B-intervention	0	4	Oral
I-intervention	5	16	ibandronate
O	17	19	is
O	20	22	as
O	23	29	active
O	30	32	as
B-control	33	44	intravenous
I-control	45	55	zoledronic
I-control	56	60	acid
O	61	64	for
O	65	73	reducing
O	74	78	bone
O	79	87	turnover
O	88	95	markers
O	96	98	in
O	99	104	women
O	105	109	with
O	110	116	breast
O	117	123	cancer
O	124	127	and
O	128	132	bone
O	133	143	metastases
O	143	144	.

O	145	150	Phase
O	151	154	III
O	155	160	study
O	161	170	comparing
O	171	174	the
O	175	181	effect
O	182	184	of
O	185	189	oral
O	190	201	ibandronate
O	202	205	and
O	206	217	intravenous
O	218	228	zoledronic
O	229	233	acid
O	234	236	on
O	237	241	bone
O	242	249	markers
O	249	250	.

B-eligibility	251	257	Breast
I-eligibility	258	264	cancer
I-eligibility	265	273	patients
I-eligibility	274	278	with
I-eligibility	279	283	bone
I-eligibility	284	294	metastases
O	295	303	received
O	304	315	ibandronate
O	316	318	50
O	319	321	mg
O	321	322	/
O	322	325	day
O	326	327	(
O	327	328	n
O	329	330	=
B-intervention-participants	331	334	137
O	334	335	)
O	336	338	or
O	339	349	zoledronic
O	350	354	acid
O	355	356	4
O	357	359	mg
O	360	365	every
O	366	367	4
O	368	373	weeks
O	374	375	(
O	375	376	n
O	377	378	=
B-control-participants	379	382	138
O	382	383	)
O	384	387	for
O	388	390	12
O	391	396	weeks
O	396	397	.

O	398	401	The
O	402	409	primary
O	410	413	end
O	414	419	point
O	420	423	was
B-outcome-Measure	424	428	mean
I-outcome-Measure	429	439	percentage
I-outcome-Measure	440	446	change
I-outcome-Measure	447	449	in
I-outcome-Measure	450	455	serum
I-outcome-Measure	456	462	levels
I-outcome-Measure	463	465	of
I-outcome-Measure	466	471	cross
I-outcome-Measure	471	472	-
I-outcome-Measure	472	478	linked
I-outcome-Measure	479	480	C
I-outcome-Measure	480	481	-
I-outcome-Measure	481	489	terminal
I-outcome-Measure	490	501	telopeptide
I-outcome-Measure	502	504	of
I-outcome-Measure	505	509	type
I-outcome-Measure	510	511	I
I-outcome-Measure	512	520	collagen
I-outcome-Measure	521	522	(
I-outcome-Measure	522	523	S
I-outcome-Measure	523	524	-
I-outcome-Measure	524	527	CTX
I-outcome-Measure	527	528	)
I-outcome-Measure	529	531	at
I-outcome-Measure	532	536	week
I-outcome-Measure	537	539	12
O	539	540	.

B-outcome-Measure	541	548	Urinary
I-outcome-Measure	549	552	CTX
I-outcome-Measure	553	554	(
I-outcome-Measure	554	555	U
I-outcome-Measure	555	556	-
I-outcome-Measure	556	559	CTX
I-outcome-Measure	559	560	)
O	560	561	,
B-outcome-Measure	562	566	bone
I-outcome-Measure	567	575	alkaline
I-outcome-Measure	576	587	phosphatase
I-outcome-Measure	588	589	(
I-outcome-Measure	589	592	ALP
I-outcome-Measure	592	593	)
O	593	594	,
B-outcome-Measure	595	600	amino
I-outcome-Measure	600	601	-
I-outcome-Measure	601	609	terminal
I-outcome-Measure	610	621	procollagen
I-outcome-Measure	622	632	propeptide
I-outcome-Measure	633	635	of
I-outcome-Measure	636	640	type
I-outcome-Measure	641	642	I
I-outcome-Measure	643	651	collagen
I-outcome-Measure	652	653	(
I-outcome-Measure	653	657	PINP
I-outcome-Measure	657	658	)
I-outcome-Measure	659	662	and
I-outcome-Measure	663	674	osteocalcin
I-outcome-Measure	675	676	(
I-outcome-Measure	676	678	OC
I-outcome-Measure	678	679	)
O	680	684	were
O	685	689	also
O	690	698	measured
O	699	702	and
O	703	707	bone
O	708	712	pain
O	713	716	and
O	717	723	safety
O	724	732	assessed
O	732	733	.

O	734	738	Both
O	739	754	bisphosphonates
O	755	768	significantly
O	769	776	reduced
B-outcome	777	778	S
I-outcome	778	779	-
I-outcome	779	782	CTX
O	783	784	(
O	784	788	mean
O	789	800	ibandronate
B-iv-cont-mean	801	803	76
I-iv-cont-mean	803	804	%
O	805	806	+
O	806	807	/
O	807	808	-
B-iv-cont-sd	809	811	29
O	812	813	(
O	813	815	SD
O	815	816	)
O	817	823	versus
O	824	828	mean
O	829	839	zoledronic
O	840	844	acid
B-cv-cont-mean	845	847	73
I-cv-cont-mean	847	848	%
O	849	850	+
O	850	851	/
O	851	852	-
B-cv-cont-sd	853	855	47
O	855	856	;
O	857	858	P
O	859	860	<
O	861	862	0
O	862	863	.
O	863	866	001
O	867	870	for
O	871	875	both
O	876	882	versus
O	883	891	baseline
O	891	892	)
O	893	896	and
B-outcome	897	898	U
I-outcome	898	899	-
I-outcome	899	902	CTX
O	903	904	(
O	904	915	ibandronate
B-iv-cont-mean	916	918	78
I-iv-cont-mean	918	919	%
O	920	921	+
O	921	922	/
O	922	923	-
B-iv-cont-sd	924	926	50
O	927	933	versus
O	934	944	zoledronic
O	945	949	acid
B-cv-cont-mean	950	952	86
I-cv-cont-mean	952	953	%
O	954	955	+
O	955	956	/
O	956	957	-
B-cv-cont-sd	958	960	17
O	960	961	;
O	962	963	P
O	964	965	<
O	966	967	0
O	967	968	.
O	968	971	001
O	971	972	)
O	972	973	.

O	974	977	The
B-outcome	978	988	difference
I-outcome	989	991	in
I-outcome	992	993	S
I-outcome	993	994	-
I-outcome	994	997	CTX
O	998	1005	between
O	1006	1016	treatments
O	1017	1020	was
O	1021	1022	0
O	1022	1023	.
O	1023	1024	6
O	1024	1025	%
O	1026	1027	(
O	1027	1037	confidence
O	1038	1046	interval
O	1047	1048	-
O	1048	1049	1
O	1049	1050	.
O	1050	1051	7
O	1051	1052	%
O	1053	1055	to
O	1056	1057	3
O	1057	1058	.
O	1058	1059	0
O	1059	1060	%
O	1060	1061	)
O	1061	1062	,
O	1063	1068	which
O	1069	1072	was
O	1073	1079	within
O	1080	1083	the
O	1084	1096	prespecified
O	1097	1111	noninferiority
O	1112	1118	margin
O	1118	1119	.

B-outcome	1120	1124	Bone
I-outcome	1125	1128	ALP
I-outcome	1128	1129	,
I-outcome	1130	1134	PINP
I-outcome	1135	1138	and
I-outcome	1139	1141	OC
O	1142	1151	decreased
O	1152	1154	by
O	1155	1157	26
O	1157	1158	%
O	1158	1159	-
O	1159	1161	47
O	1161	1162	%
O	1163	1171	compared
O	1172	1176	with
O	1177	1185	baseline
O	1186	1190	with
O	1191	1195	both
O	1196	1211	bisphosphonates
O	1211	1212	.

O	1213	1221	Compared
O	1222	1226	with
O	1227	1237	zoledronic
O	1238	1242	acid
O	1242	1243	,
O	1244	1255	ibandronate
O	1256	1264	patients
O	1265	1273	reported
O	1274	1279	fewer
B-outcome	1280	1287	adverse
I-outcome	1288	1294	events
I-outcome	1295	1302	overall
O	1303	1304	(
B-iv-bin-percent	1304	1306	65
I-iv-bin-percent	1306	1307	.
I-iv-bin-percent	1307	1308	0
I-iv-bin-percent	1308	1309	%
O	1310	1316	versus
B-cv-bin-percent	1317	1319	75
I-cv-bin-percent	1319	1320	.
I-cv-bin-percent	1320	1321	9
I-cv-bin-percent	1321	1322	%
O	1322	1323	)
O	1323	1324	,
O	1325	1328	and
O	1329	1331	on
B-outcome	1332	1336	days
I-outcome	1337	1338	1
I-outcome	1338	1339	-
I-outcome	1339	1340	3
O	1341	1342	(
B-iv-bin-percent	1342	1343	8
I-iv-bin-percent	1343	1344	.
I-iv-bin-percent	1344	1345	0
I-iv-bin-percent	1345	1346	%
O	1347	1353	versus
B-cv-bin-percent	1354	1356	47
I-cv-bin-percent	1356	1357	.
I-cv-bin-percent	1357	1358	5
I-cv-bin-percent	1358	1359	%
O	1359	1360	)
O	1360	1361	,
O	1362	1371	including
O	1372	1376	less
B-outcome	1377	1384	pyrexia
O	1385	1386	(
O	1386	1393	overall
O	1394	1403	incidence
B-iv-bin-percent	1404	1405	0
I-iv-bin-percent	1405	1406	%
O	1407	1413	versus
B-cv-bin-percent	1414	1416	16
I-cv-bin-percent	1416	1417	.
I-cv-bin-percent	1417	1418	8
I-cv-bin-percent	1418	1419	%
O	1419	1420	)
O	1421	1424	and
B-outcome	1425	1429	bone
I-outcome	1430	1434	pain
O	1435	1436	(
B-iv-bin-percent	1436	1437	5
I-iv-bin-percent	1437	1438	.
I-iv-bin-percent	1438	1439	8
I-iv-bin-percent	1439	1440	%
O	1441	1447	versus
B-cv-bin-percent	1448	1450	12
I-cv-bin-percent	1450	1451	.
I-cv-bin-percent	1451	1452	4
I-cv-bin-percent	1452	1453	%
O	1453	1454	)
O	1454	1455	.

O	1456	1460	Oral
O	1461	1472	ibandronate
O	1473	1476	was
O	1477	1481	well
O	1482	1491	tolerated
O	1492	1495	and
O	1496	1509	statistically
O	1510	1521	noninferior
O	1522	1524	to
O	1525	1535	zoledronic
O	1536	1540	acid
O	1541	1544	for
O	1545	1555	percentage
O	1556	1562	change
O	1563	1565	in
O	1566	1569	the
O	1570	1574	bone
O	1575	1585	resorption
O	1586	1592	marker
O	1592	1593	,
O	1594	1595	S
O	1595	1596	-
O	1596	1599	CTX
O	1599	1600	.
